| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $75,770 | 6 | 30 |
Sells | $16,473,455 | 14 | 70 |
| BIENAIME JEAN JACQUES | director | 6 | $75,770 | 0 | $0 | $75,770 |
| Newton Charles W. | director | 0 | $0 | 2 | $11,197 | $-11,197 |
| Tanini Annita | Corp. Controller & VP, Finance | 0 | $0 | 1 | $12,595 | $-12,595 |
| Seth Alpna | director | 0 | $0 | 1 | $28,140 | $-28,140 |
| Farzan Nima | director | 0 | $0 | 1 | $28,166 | $-28,166 |
| Knowles Julius | director | 0 | $0 | 1 | $28,166 | $-28,166 |
| Regnante Keith | CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $77,483 | $-77,483 |
| Lerner Lorena Raquel | Chief Science Officer | 0 | $0 | 2 | $100,038 | $-100,038 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | 0 | $0 | 1 | $113,433 | $-113,433 |
| Cho Esther | SVP, General Counsel | 0 | $0 | 2 | $123,731 | $-123,731 |
| Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 0 | $0 | 1 | $2.76M | $-2.76M |
| ADAR1 Capital Management, LLC | 10 percent owner | 0 | $0 | 1 | $13.19M | $-13.19M |
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Over the last 12 months, insiders at Keros Therapeutics, Inc. have bought $75,770 and sold $16.47M worth of Keros Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Keros Therapeutics, Inc. have bought $4.77M and sold $15.41M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BIENAIME JEAN JACQUES (director) — $75,770.
The last purchase of 1,000 shares for transaction amount of $10,270 was made by BIENAIME JEAN JACQUES (director) on 2026‑08‑17.
| 2026-08-18 | Sale | Tanini Annita | Corp. Controller & VP, Finance | 1,224 0.0037% | $10.29 | $12,595 | +4.62% | |
| 2026-08-18 | Sale | Cho Esther | Chief Legal Officer | 4,485 0.0136% | $10.29 | $46,151 | +4.62% | |
| 2026-08-18 | Sale | Lerner Lorena Raquel | Chief Scientific Officer | 3,568 0.0108% | $10.29 | $36,715 | +4.62% | |
| 2026-08-18 | Sale | Newton Charles W. | director | 551 0.0017% | $10.30 | $5,675 | +4.62% | |
| 2026-08-17 | BIENAIME JEAN JACQUES | director | 1,000 0.0049% | $10.27 | $10,270 | +5.82% | ||
| 2026-07-15 | BIENAIME JEAN JACQUES | director | 1,000 0.003% | $10.61 | $10,610 | -3.54% | ||
| 2026-06-15 | BIENAIME JEAN JACQUES | director | 1,000 0.0031% | $10.19 | $10,190 | +5.27% | ||
| 2026-06-11 | Sale | Newton Charles W. | director | 550 0.0017% | $10.04 | $5,522 | +6.47% | |
| 2026-06-04 | Sale | Knowles Julius | director | 2,625 0.0082% | $10.73 | $28,166 | -1.07% | |
| 2026-06-04 | Sale | Seth Alpna | director | 2,625 0.0082% | $10.72 | $28,140 | -1.07% | |
| 2026-06-04 | Sale | Farzan Nima | director | 2,625 0.0082% | $10.73 | $28,166 | -1.07% | |
| 2026-05-15 | BIENAIME JEAN JACQUES | director | 1,000 0.0031% | $10.58 | $10,580 | +1.90% | ||
| 2026-04-15 | BIENAIME JEAN JACQUES | director | 1,000 0.0027% | $11.70 | $11,700 | -6.15% | ||
| 2026-03-09 | BIENAIME JEAN JACQUES | director | 2,000 0.0053% | $11.21 | $22,420 | -2.82% | ||
| 2026-02-19 | Sale | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | 7,015 0.0173% | $16.17 | $113,433 | -33.05% | |
| 2026-02-18 | Sale | Cho Esther | SVP, General Counsel | 4,745 0.0118% | $16.35 | $77,581 | -31.42% | |
| 2026-02-18 | Sale | Regnante Keith | CHIEF FINANCIAL OFFICER | 4,739 0.0118% | $16.35 | $77,483 | -31.42% | |
| 2026-02-18 | Sale | Lerner Lorena Raquel | Chief Science Officer | 3,873 0.0097% | $16.35 | $63,324 | -31.42% | |
| 2025-10-15 | Sale | Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 155,262 0.4683% | $17.75 | $2.76M | -19.32% | |
| 2025-10-15 | Sale | ADAR1 Capital Management, LLC | 10 percent owner | 743,358 2.1529% | $17.75 | $13.19M | -19.32% |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | 385708 1.2054% | $4.37M | 1 | 1 | +122.73% |
| Tanini Annita | Corp. Controller & VP, Finance | 45144 0.1411% | $511,030.08 | 0 | 1 | |
| Regnante Keith | CHIEF FINANCIAL OFFICER | 39261 0.1227% | $444,434.52 | 0 | 5 | |
| Cho Esther | Chief Legal Officer | 35770 0.1118% | $404,916.40 | 0 | 2 | |
| Lerner Lorena Raquel | Chief Scientific Officer | 27559 0.0861% | $311,967.88 | 0 | 2 | |
| BIENAIME JEAN JACQUES | director | 19592 0.0612% | $221,781.44 | 6 | 0 | |
| Newton Charles W. | director | 12114 0.0379% | $137,130.48 | 0 | 2 | |
| Knowles Julius | director | 10958 0.0342% | $124,044.56 | 1 | 39 | +122.73% |
| Seth Alpna | director | 9767 0.0305% | $110,562.44 | 0 | 1 | |
| Farzan Nima | director | 9767 0.0305% | $110,562.44 | 0 | 1 | |
| Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 0 0% | $0 | 2 | 1 | +51.74% |
| ADAR1 Capital Management, LLC | 10 percent owner | 0 0% | $0 | 1 | 1 | +45.5% |
| Kariv Tomer | 2288151 7.1509% | $25.9M | 2 | 0 | +51.74% | |
| Nussbaum Ran | 2288151 7.1509% | $25.9M | 2 | 0 | +51.74% | |
| Lazarus Alon | 2013102 6.2913% | $22.79M | 1 | 0 | +122.73% | |
| Arkin Bio Ventures Limited Partnership | 10 percent owner | 2013102 6.2913% | $22.79M | 1 | 0 | +122.73% |
| ORBIMED ADVISORS LLC | director | 119522 0.3735% | $1.35M | 1 | 1 | +122.73% |
| GORDON CARL L | director | 119522 0.3735% | $1.35M | 1 | 1 | +122.73% |
| Lachey Jennifer | Chief Scientific Officer | 95100 0.2972% | $1.08M | 0 | 19 | |
| Rovaldi Christopher | Chief Operating Officer | 0 0% | $0 | 0 | 2 | |
| Ordonez Claudia | Chief Medical Officer | 0 0% | $0 | 0 | 5 |
$23,426,322 | 55 | 18.10% | $363.71M | |
$140,595,157 | 34 | 17.93% | $343.13M | |
$121,435,814 | 28 | 12.32% | $383.99M | |
$109,019,806 | 28 | 7.36% | $397.87M | |
$3,668,031 | 23 | 2.05% | $341.97M | |
$15,509,325 | 19 | 7.10% | $326.54M | |
Keros Therapeutics, Inc. (KROS) | $101,822,203 | 13 | 84.03% | $362.22M |
$10,399,379 | 13 | 13.60% | $409.42M | |
$189,648 | 9 | -52.20% | $338.47M | |
$2,762,881 | 8 | -10.76% | $330.08M | |
$747,947 | 6 | 10.18% | $352.13M | |
$556,839 | 5 | 13.42% | $415.73M | |
$208,592 | 4 | 11.22% | $385.58M | |
$58,352 | 4 | -43.78% | $322.23M | |
$51,688 | 4 | -26.18% | $381.05M | |
$10,104,842 | 3 | 5.45% | $383.97M | |
$37,067 | 3 | -89.81% | $362.78M | |
$950,400 | 1 | 133.43% | $324.18M | |
$63,731 | 1 | -19.50% | $356.44M |
| Increased Positions | 85 | +41.26% | 5M | +15.53% |
| Decreased Positions | 97 | -47.09% | 20M | -57.95% |
| New Positions | 45 | New | 1M | New |
| Sold Out Positions | 25 | Sold Out | 7M | Sold Out |
| Total Postitions | 194 | -5.83% | 20M | -42.42% |
| Adar1 Capital Management, Llc | $99,917.00 | 17.96% | 5.39M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $50,406.00 | 9.06% | 2.72M | +87,129 | +3.31% | 2025-09-30 |
| Blackrock, Inc. | $50,376.00 | 9.06% | 2.72M | -15,470 | -0.57% | 2025-09-30 |
| Madison Avenue Partners, Lp | $50,210.00 | 9.03% | 2.71M | +16,753 | +0.62% | 2025-09-30 |
| Western Standard Llc | $40,600.00 | 7.3% | 2.19M | +654,989 | +42.67% | 2025-09-30 |
| Tang Capital Management Llc | $26,308.00 | 4.73% | 1.42M | 0 | 0% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $24,685.00 | 4.44% | 1.33M | +34,042 | +2.62% | 2025-09-30 |
| Goldman Sachs Group Inc | $24,574.00 | 4.42% | 1.33M | +441,923 | +50.02% | 2025-09-30 |
| State Street Corp | $24,157.00 | 4.34% | 1.3M | -81,276 | -5.87% | 2025-09-30 |
| Nantahala Capital Management, Llc | $22,863.00 | 4.11% | 1.23M | -387,503 | -23.91% | 2025-09-30 |